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Massachusetts Department of Public Health 
Bureau of Healthcare Safety and Quality  
Medical Use of Marijuana Program 
 
Response to Public Comments 
 
February 12, 2016 
 
This document provides the Massachusetts Department of Public Health (DPH) response to 
public comments received as part of the open comment period on the Protocol for Sampling and 
Analysis of Finished Medical Marijuana Products and Marijuana Infused Products for 
Massachusetts Registered Medical Marijuana Dispensaries that was released as a Revised Draft 
for Public Comment on November 20, 2015 (“Revised Protocol”).   
 
The Revised Protocol provides regulatory guidance for Registered Marijuana Dispensaries 
(RMD) and/or analytical testing laboratories conducting product testing in compliance with the 
Department of Public Health (DPH) Regulations regarding the medical use of marijuana, 105 
CMR 725.000 et seq. 
 
The following 18 comments or questions were drawn from approximately 185 comments 
submitted on the Revised Protocol.  As many individuals submitted similar or identical 
comments or questions, the 18 comments or questions below may represent the combination of 
similar comments or questions by one or more individuals.      
 
1) The new DPH Protocol on hydrocarbon extraction (e.g., using butane to produce 
cannabis concentrate), will restrict dispensaries from serving patients and limit 
patients’ access to their preferred form of medical marijuana.  
 
The Revised Protocol does not restrict the use of butane when extracting oils from cannabis 
flower.  The Revised Protocol requires that when butane is used in the extraction process, the 
levels of butane may only be present at safe levels in the finished product.  
 
2) The strict set of standards proposed by DPH will force patients to pursue marijuana 
products from the expensive and unregulated grey/black market. Support of the 
grey/black market may endanger the health of patients and the suppliers who make the 
products, since chemicals can be dangerous if they are used incorrectly or remain in 
finished product. Less restrictive regulations will help eliminate the risks associated 
with the grey/black market and encourage the development of a better quality product. 
 
DPH is committed to ensuring that patients have access to the safest form of medical 
marijuana.  The Revised Protocol is based on the standards used in the manufacturing of 
pharmaceutical products.  DPH recognizes the hazard potential of chemical contaminants and 
has based the current standards on established best practices.  The contaminant limits have 
been established to be health protective and are comparable to standards used for over-the-
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counter drugs, rather than illegal narcotics.  DPH is committed to ensuring patient access to 
products that are free of contamination.    
 
3) Using hydrocarbons for the production of marijuana concentrates and other products 
is essential to the health and well-being of patients and allows patients to explore more 
options for methods of use other than smoking (e.g., vaping and edibles). Hydrocarbons 
are safe if they are used correctly and are removed from the final product. Strict 
hydrocarbon standards are limiting research and development of improved marijuana 
products for patients.   
 
The Revised Protocol allows for the use of hydrocarbons.  DPH agrees that hydrocarbons are 
safe if used correctly and removed from the final product. 
 
4) Other states with medical marijuana laws already have established limits for 
hydrocarbons in finished products. The limits in other states are far less restrictive than 
those proposed by DPH (e.g., 800 ppm).  DPH allows the use of chemicals that are 
carcinogens, while other states do not.  How did DPH develop its levels?  
 
The marijuana regulations in various states are constantly evolving.  Each state program has 
been established with different laws, and the legal use of marijuana differs in each state.  For 
example, some states do not allow some forms of marijuana (e.g., dried flower).  Therefore, 
direct state-by-state comparisons are difficult.     
 
Comments submitted on the DPH Draft Protocol appear to recommend the use of an 
inhalation (air) standard of 800 ppm for a healthy adult worker to establish a residual solvent 
standard for a medical marijuana patient.  This is not a health-protective approach.  Exposure 
standards developed for healthy adult workers are not the same as standards developed for 
potentially very ill patients.  In addition, an air concentration of 800 ppm of butane is not the 
same as 800 mg/kg of butane in an edible marijuana product.  Air concentrations described in 
ppm refer to a volume-based ratio of a volume of gas mixed in a million volumes of air.  
 
The DPH upper limits for residual solvents are drawn from the limits described in US 
Pharmacopoeia (USP) (Chapter <467>).  The USP has established standards for over 50 
residual solvents that are used in the manufacturing of chemical and biological drug 
substances, dosage forms, compounded preparations, excipients, medical devices, and dietary 
supplements sold in the United States.   
 
As the USP does not have a standard for butane (propane, n-butane and iso-butane), DPH 
based the residual solvent limit on the Commission of the European Communities, Scientific 
Committee on Food Recommendations (SCF). SCF has evaluated propane, n-butane and iso-
butane as extraction solvents and determined that a residue level of 1 mg of residual 
hydrocarbon per kg of food consumed is safe. The SCF evaluation suggests that these 
hydrocarbons are typically present in prepared foods in amounts less than 0.1 mg/kg. After 
careful review of the SCF assessment, DPH has adopted a level of 1 mg/kg (or 10 times the 
background level of 0.1 mg/kg) as a health-protective residual solvent limit for cannabis oils. 
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DPH is continuing to engage stakeholders on opportunities to refine the interim guidance on 
butane informed by (a) laboratory reports and data packages describing the measurement of 
butane in medical marijuana products sold in Massachusetts; and (b) analyses prepared by 
consultants describing a proposed health-based standard.       
 
5) The scientific evidence supporting the proposed DPH Protocol is unclear or nonexistent. 
No specific level (ppm) has been proven as unsafe. People inhale higher levels of the 
regulated chemicals from the lighter used to smoke the marijuana, or even from the air 
in the environment.  DPH should postpone the establishment of restrictive levels until 
there is more scientific evidence.  
 
DPH is required by law to develop a regulatory framework to ensure that qualified patients 
have timely access to safe marijuana for medical use.  The Revised Protocol has been 
established using specific levels that are published in authoritative sources such as the United 
States Pharmacopeia and the European Union Commission of the European Communities, 
Scientific Committee on Food.  For example, the USP-based approach is the international 
standard for all manufactured pharmaceutical products. 
 
The USP approach has the added advantage of utilizing an established system where all 
stakeholders have the opportunity for input.  This is because the USP standards are 
developed and changed in an open and collaborative process, seeking informed input from 
independent experts with a wide variety of backgrounds – healthcare, regulatory, industry, 
academia, and others.  By adopting this approach, we are ensuring that the process is 
credible, rigorous, and provides a high level of public assurance that the standard has been 
developed using a broadly representative body of science.   
 
6) DPH should clarify the difference between the amount that a patient can be prescribed 
and the amount that can be purchased.   
 
A physician “certifies” instead of “prescribes” a qualifying patient for marijuana.  A 
physician may certify a patient for marijuana for no less than 15 days and up to a year, but 
within the period of time that certification is valid, a qualifying patient may only be 
dispensed a 60 day supply at a time.  A physician may certify a patient for 10 ounces of 
marijuana for that 60 days or another amount, if the physician documents the rationale for 
doing so in compliance with the Regulations.  A patient may be dispensed up to that certified 
amount within that 60 days and may not be dispensed more until the 60 days has expired.  
Due to the limitations of the testing capacity on the laboratories currently operating within 
Massachusetts, RMDs have sought waivers from testing requirements for certain 
contaminants.  To protect patient safety until the laboratories are able to test for the required 
contaminants, the waivers are conditioned upon RMDs selling no more than 4.23 ounces to a 
qualifying patient over a 60 day period.   
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7) The current cost of medical marijuana is a problem for patients. Eliminating the strict 
regulations proposed by DPH will lower the cost. Dispensaries have spent a lot of 
money to treat patients effectively, an effort which will go to waste if the strict 
regulations are maintained.   
 
DPH is committed to ensuring that patients have access to the safest form of medical 
marijuana.  The Revised Protocol is based on the standards used in the manufacturing of 
pharmaceutical products.   
 
8) It seems like DPH is establishing strict regulations to slow the progress of the medical 
marijuana business and restrict access to patients who need it. There are further 
actions that DPH should take to support the medical marijuana market and the 
patients in Massachusetts: 
 
a. DPH should open a state-run facility to test for chemicals like those in fertilizers and 
in final marijuana products sold to patients.   
 
DPH does not regulate or operate laboratories that test marijuana for medical use.  The 
Regulations state that all testing must be conducted by an independent laboratory that is 
accredited to International Organization for Standardization (ISO) 17025 by a third party 
accrediting body such as A2LA or ACLASS, or certified, registered, or accredited by an 
organization approved by the Department. 
 
b. DPH should require that medical marijuana products be prescribed like 
pharmaceuticals. Physicians should be required to learn about the features of 
medical marijuana, such as the different strains, routes of administration, etc.   
 
The Revised Protocol describes a process to evaluate marijuana for medical use to ensure that 
contaminants such as residual solvents, heavy metals, and microbial contamination are not 
present.  The Revised Protocol does not place any restrictions or establish guidelines for the 
prescription of marijuana for medical use.   Physicians who certify marijuana for medical use 
are required to undergo continuing education regarding the medical use of marijuana, 
including side effects, dosage, and contraindications, including with psychotropic drugs, as 
well as on substance abuse recognition, diagnosis, and treatment related to marijuana. 
 
c. DPH should regulate medical marijuana in a way similar to the regulation of 
alcohol and prescriptions.  
 
The Revised Protocol has been established using procedures drawn from the United States 
Pharmacopeia.  The USP has established standards for chemical and biological drug 
substances, dosage forms, compounded preparations, excipients, medical devices, and dietary 
supplements for any products sold in the United States.  These standards are the same 
standards that are applied to prescription drugs sold in the United States. 
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d. DPH should clearly explain its regulation decisions to the public. 
 
Detailed information regarding DPH regulations decisions may be found at the following 
website:   
 
http://www.mass.gov/eohhs/gov/departments/dph/programs/hcq/medical-marijuana/ 
 
e. DPH should conduct ongoing research on medical marijuana. 
 
DPH is evaluating ways to support research into the medical use of marijuana and will provide 
further information when it is available. 
 
9) A different profile of pharmacologically active compounds results when using 
hydrocarbons for extraction than when CO2 is used. Marijuana products made from 
hydrocarbon extraction processes should be available to patients if desired. 
 
The Revised Protocol describes a process to evaluate medical marijuana to ensure that 
contaminants such as residual solvents, heavy metals, and microbial contamination are not 
present.  The Revised Protocol does not describe an evaluation of the pharmacologically active 
compounds in cannabis.  The Revised Protocol does not restrict the use of the hydrocarbon 
butane when extracting oils from cannabis flower.  The protocols require that when butane is 
used in the extraction process, the levels of butane are present at safe levels. 
 
10) It appears from the November 20th presentation that DPH proposes 10/g day of medical    
marijuana - that would make the 60 day supply 600g or 21 oz? 
 
DPH regulations allow a physician to certify a patient for 10 ounces of marijuana for 60 days, or 
another amount, if the physician documents the rationale for doing so in compliance with the 
Regulations.  In the Revised Protocol, the heavy metal limits are based on United States 
Pharmacopeia (USP) standards applicable for pharmaceuticals that have a maximum use of 10 
g/day.  In the November 20
th
 presentation, we wanted to illustrate that this is the maximum 
amount of product that should be consumed in any given day.  This is not the same as saying that 
the regulations allow a patient to obtain 10 g of marijuana every day.     
 
11) The 10 ppb level for Pesticides and Plant Growth Regulators in Exhibit 5 seems low in 
comparison to the USDA maximum allowed samples, which ranges from 10-fold to 
1000-fold higher than the recommended ppb.  Consider changing this pesticide 
screening approach, and eliminate some of the pesticides that DPH requires to be 
evaluated. 
 
The USDA (2012a) Laboratory Selection Criteria for Pesticide Residue Testing that is referenced 
in the Revised Protocol is useful as a guide for analytical testing laboratories to ensure that any 
pesticides and plant growth regulators that are used in the cultivation of marijuana (e.g., nutrient 
solutions, fertilizer, grow media, soil amendment, etc.) that would be prohibited under the USDA 
Organic Agriculture Program, would also be prohibited for use in the cultivation of marijuana in 
Massachusetts.   
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Since the November 2015 release of the draft Revised Protocol, DPH has made interim revisions 
to the “Minimum Analysis Requirements for Residues of Pesticides and Plant Growth Regulators 
Commonly Used in Cannabis Cultivation,” and will be developing Final Guidance over the next 
year. 
 
The interim guidance allows a laboratory that is unable to perform the required testing of 
pesticide residues at or below the 10 parts per billion (ppb) criteria to determine compliance by 
ensuring that any pesticide residues are present at a level less than or equal to 5 percent of the 
US EPA tolerance for the specific residue.  EPA pesticide tolerances are available from Title 40 
of the Code of Federal Regulations (CFR).  The interim guidance has also removed 9 pesticides 
from the list of required analytes on Exhibit 5 (i.e., Abamectin, Acequinocyl, Chlormequat 
chloride, Daminozide, Fenoxycarb, Paclobutrazol, Natural Pyrethrins, Spinosad, Spirotetramat).     
 
Over the next year a revised approach for the testing and analysis of pesticides/plant growth 
regulators will be developed.  DPH is working with stakeholders as well as local, state and 
national experts to refine this approach.  The current strategy is to develop a list of pesticides and 
plant growth regulators that are being specifically applied to finished marijuana plants or 
products.  This list will be informed by the continually evolving best practices of state agencies 
charged with the ensuring the safety of medical use of marijuana programs, and the state-of-the-
science on available analytical laboratory methods to measure pesticide residues on cannabis 
plants. 
 
12) The drying of marijuana products may alter the potency profile (cannabinoid) content 
of the product.  As THC and CBD molecules are recognized by some patients and 
physicians as being important in treatment, DPH should encourage the testing of THC-
A and CBD-A in cannabinoid profiles of unheated materials.  
 
The Revised Protocol describes testing medical marijuana to ensure that contaminants are not 
present and patients have access to safe product.  In general, the Revised Protocol describes  
“Minimum Analysis Requirements” and do not describe a comprehensive evaluation of the 
pharmacologically active compounds in cannabis.  While the Revised Protocol does not place 
any restrictions or establish guidelines for the prescription of certain types of marijuana for 
medical use, or analysis that may be performed in addition to the minimum requirements, it 
should be noted that THC-A and CBD-A have been added to the cannabinoid profile testing 
requirements 
 
13) DPH should raise the maximum allowable levels of Cd and Pb to match the USDA 
standards for ingestible products. 
 
The Revised Protocol adopts upper limits for heavy metal contaminants that have been 
established by the United States Pharmacopeia (USP).   These standards have been developed 
specifically for drugs sold in the United States.   The USP standards in the National Formulary 
(NF) are also the official enforceable standards for pharmaceutical product strength, quality and 
purity by the FDA.     
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14) DPH should only require the testing for the individual solvents if the solvent has been 
used in the processing of the plant for that product. 
 
The Revised Protocol states that cannabis concentrates must only be tested for residual solvents 
if the solvents were used in their production. Specifically, testing is required for a solvent if that 
solvent was used to manufacture a concentrate.   
 
15) Laboratories performing MMJ testing should follow the guidelines for personnel 
similar to CLIA and DPH regulations for clinical laboratories. 
 
While DPH has developed a process to provide an evaluation of laboratory capability, DPH does 
not regulate or operate laboratories that test marijuana for medical use.  The Regulations state 
that all testing must be conducted by an independent laboratory that is accredited to International 
Organization for Standardization (ISO) 17025 by a third party accrediting body such as A2LA or 
ACLASS, or certified, registered, or accredited by an organization approved by the Department.   
 
16) Regulations require medical cannabis to be grown organically. Organic soil and organic 
nutrients may contain higher levels of arsenic and heavy metals. Tests could result in 
higher levels because of it.  
 
The Revised Protocol references the USDA Organic Program as a guide to ensure that any 
pesticides that are prohibited under the USDA Organic Agriculture program, are also prohibited 
for use in the cultivation of marijuana in Massachusetts.  The Revised Protocol requires the 
testing of finished plant material to ensure that pesticides and plant growth regulators have not 
been used.   
 
Both soil and soil amendments must be tested for heavy metals long before they are ever used in 
the cultivation of cannabis plants.  This testing is covered in the “Protocol for Sampling and 
Analysis of Environmental Media for Massachusetts Registered Medical Marijuana 
Dispensaries.”       
 
17) The heavy metal standards are based on two different routes of exposure (e.g., ingestion 
or inhalation).  Why was this approach not taken for residual solvent levels? 
 
The Revised Protocol refers to an approach to evaluate heavy metal contaminants and residual 
solvents that have been established by the United States Pharmacopeia.   This is a significant 
point as this approach adopts USP standards and did not develop them.  While the USP has a 
different heavy metal standard for inhalation and ingestion, respectively, it does not have two 
different standards for residual solvents. 
 
18) DPH should explain the “10 gram/day” assumption described in the derivation of the 
Heavy Metal Standards. 
 
In the Revised Protocol, the heavy metal limits are based on concentrations listed in the United 
States Pharmacopeia (USP) document describing Elemental Impurities (i.e., metals).  The 
Recommended Limits for Metals (Protocol Exhibit 4) have been adopted by DPH based on USP 
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calculations of concentration limits for components (drug substances and excipients), that 
assume products will be used at any dose up to a maximum daily dose of 10 grams per day.  
These values are default concentration limits that are set by USP for manufacturers and suppliers 
of drug products.  The 10 g/day value was not used quantitatively by DPH to calculate a 
concentration limit.  As the USP limit is applicable for any use up to a maximum of 10 g/day, we 
wanted to ensure that patients understand that this is the maximum amount of product that should 
be consumed in any given day.  We recognize that most patients will use much less than this 
amount.   
 
 
  
